This protocol was terminated prematurely because the prior principal investigator departed the Institute without treating any participants.

Background:

Cancers of the female reproductive organs often come back after treatment. A drug called sacituzumab govitecan (SG) has been approved for use in other types of cancers. Researchers want to see if SG can also help people with ovarian, endometrial, or cervical cancers.

Objective:

To test SG in people with ovarian, endometrial, or cervical cancers.

Eligibility:

People aged 18 years and older with ovarian, endometrial, or cervical cancer. Their cancers must have returned after at least 2 rounds of standard treatments.

Design:

Participants will be screened. They will have a physical exam with blood and urine tests. They will have imaging scans and a test of their heart function. They also will have biopsies to get new tissues samples taken from their tumors.

SG is infused through a tube attached to a needle inserted into a vein in the arm. Treatment will be given in 21-day cycles. Participants will receive SG on days 1 and 8 of each cycle. Each infusion takes 1 to 3 hours.

Participants may receive SG for up to 5 years. They can continue as long as the drug is helping them. Imaging scans and other tests will be repeated throughout the study period.

Participants will have an end-of-treatment visit within 2 weeks and a safety visit about 30 days after they stop treatment. Physical exams, blood tests, and imaging scans may be repeated.

Participants will then be contacted by phone every 6 months for up to 10 years after their first dose of SG.

Sponsoring Institution:

National Cancer Institute...

Background:

• Human trophoblast cell-surface marker (TROP2) is a surface glycoprotein originally identified in human placental tissue and highly expressed in gynecologic malignancies. TROP2 overexpression in ovarian, endometrial, and cervical cancers is linked to tumorigenicity and poor overall survival.
• Sacituzumab govitecan (SG) is an antibody-drug conjugate (ADC) of an Immunoglobulin G (IgG(kappa)1 monoclonal antibody targeting TROP2 with a chemotherapeutic payload of SN-38. SN-38 is an active metabolite of irinotecan and acts as a topoisomerase I inhibitor.
• Preclinical data suggest that SG induces deoxyribonucleic acid (DNA) damage, replication stress, and tumor shrinkage in drug-resistant ovarian, endometrial, and cervical cancer in vitro and in vivo preclinical models.
• Further clinical and translational studies are needed to better understand SGs clinical activity and biology in relapsed gynecologic cancer patients.

Objective:

-To determine the objective response rate (ORR) of sacituzumab govitecan (SG) in participants with recurrent gynecological malignancies, calculated for each individual tumor histology by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Eligibility:

• Age >= 18 years
• Eastern Cooperative Oncology Group (ECOG) performance status <= 1
• Histologically documented, recurrent platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancer (referred to as ovarian cancer); recurrent endometrioid or serous endometrial cancer; or recurrent epithelial cervical cancer
• At least two prior systemic therapeutic regimens
• Measurable disease by RECIST v1.1 criteria with lesions that can be safely biopsied
• No prior TROP2-targeting antibody drug conjugates (ADC)

Design:

• This is an open label, non-randomized Phase II pilot study with one Arm.
• SG will be administered intravenously (IV) at 10 mg/kg on Days 1 and 8 each 21-day cycle.
• Tumor assessments will be time-based: every 9 weeks (+/- 1 week) for the first year and every 12 weeks (+/- 1 week) thereafter until disease progression. Pre-treatment biopsies and serial blood samples will be collected for the correlative studies.
• Treatment will be given for a maximum of 5 years or until disease progression or unacceptable toxicities.
• Up to 66 evaluable participants will be enrolled.

• INCLUSION CRITERIA:

Cohort 1 (Ovarian Cancer)

• Participants must have histologically or cytologically confirmed recurrent platinum-resistant (defined as less than six months of platinum-free interval) epithelial (i.e., high grade serous, endometrioid, low grade serous, or clear cell) ovarian carcinoma that is refractory to standard treatment.
• Participants with known BReast CAncer gene (BRCA) mutated tumors should have received a poly(ADP-ribose) polymerase (PARP) inhibitor maintenance or treatment.
• Participants without known BRCA mutation and platinum-resistant tumors must have had prior bevacizumab or not eligible for bevacizumab-based therapy (i.e., history of proteinuria).

Cohort 2 (Endometrial Cancer)

• Participants must have histologically or cytologically confirmed recurrent epithelial (i.e., endometrioid or serous) endometrial carcinoma that is refractory to standard treatment.
• Participants must have received prior anti-programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1)-based therapy or not eligible for anti-PD-1/PD-L1-based therapy.

Cohort 3 (Cervical Cancer)

-Participants must have histologically or cytologically confirmed recurrent epithelial cervical (i.e. squamous or adeno) carcinoma that is refractory to standard treatment.

Note: Participants with a history of human papilloma virus infection (i.e., positive human papillomavirus (HPV deoxyribonucleic acid (DNA testing) are eligible.

-Participants must have received prior bevacizumab-based therapy or not eligible for bevacizumab-based therapy (i.e., history of proteinuria).

Note: Platinum chemotherapy administered concurrent with primary radiation (i.e., weekly cisplatin) is not counted as a systemic chemotherapeutic regimen for management of persistent or recurrent carcinoma of the cervix.

All Cohorts

• Participants must have received at least two systemic therapies including at least one platinum-based therapy regimen.

• Participants must have radiographically measurable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, and safely biopsiable lesion.

• Age >= 18 years

• Eastern Cooperative Oncology Group (ECOG) performance status <= 1

• Adequate organ and marrow function as defined below:

  • Hemoglobin (Hgb) >= 9.0 g/dL
  • Absolute neutrophil count (ANC) >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • White Blood Cell count (WBC) >= 3,000/mcL
  • Total bilirubin <= 1.5 x upper limit of normal (ULN) (<= 3 x ULN in participants with known/suspected Gilbert's disease)
  • Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) <= 2.5 x ULN
  • Serum creatinine <= 1.5 x ULN or estimated glomerular filtration rate (GFR) >= 30 ml/min/1.73 m^2

• Participants with suspicion or prior history of treated central nervous system (CNS) metastases with no evidence of active disease (assessed by magnetic resonance imaging (MRI) or contrast computed tomography (CT) scan of the brain and spinal column) are eligible if pretreatment brain MRI demonstrate no evidence of disease in the past 4 weeks prior to entry.

• Major surgical procedure, other than for diagnosis, must not occur within 4 weeks prior to the first dose of study treatment. Participants must have recovered adequately from the toxicity and/or complications from the intervention prior to starting the study drug.

• Participants with prior cancer-directed therapy must have a washout period of 3 weeks prior to the first dose of study treatment.

• Participants with prior cancer-directed immunotherapy-based therapy must have a washout period of 4 weeks prior to the first dose of study treatment.

• Human immunodeficiency virus (HIV)-infected participants are eligible if on stable dose of highly active antiretroviral therapy (HAART), a cluster of differentiation 4 (CD4) count >= 200 cells/mcL, and an undetectable viral load (VL).

• Hepatitis B virus (HBV) positive participants are eligible if they have been treated or are on an appropriate course of antivirals at study entry.

• Participants with a history of hepatitis C virus (HCV) infection (i.e., positive HCV antibody test) must have been treated and cured (undetectable HCV VL at screening). Participants with HCV infection who are currently on treatment are eligible if they have an undetectable HCV VL.

• Individuals of child-bearing potential (IOCBP) must agree to use an effective method of contraception (barrier, surgical sterilization, abstinence) prior to study entry, for the duration of study participation, and for at least 6 months after the last dose of study drug.

• IOCBP must undergo pregnancy testing at screening and must not be pregnant in order to take part. Note: In these cases, a negative Beta-human chorionic gonadotropin (Beta-human chorionic gonadotropin (hCG) (urine or blood) is required.

• Nursing participants must discontinue nursing and/or not begin nursing until 1 month after the last dose of study drug.

• Ability of participants to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

• Participants who are receiving any other investigational agents

• Primary platinum-refractory ovarian cancer (defined as progression while on the upfront platinum-based therapy)

• Participants with any other concomitant invasive malignancies

• History of severe hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to sacituzumab govitecan (SG), Camptosar; irinotecan; 7-ethyl-10-{4-[1-piperidino]-1-piperidino}carbonyoxycamptothecin (SN-38), or irinotecan.

• Prior treatment with trophoblast cell-surface marker (TROP2)-targeting antibody drug conjugates (ADC). Participants with prior use of other ADCs are eligible.

• Prior treatment with topoisomerase 1 inhibitors i.e., topotecan

• Symptomatic or untreated brain/central nervous system (CNS) metastases

• Participants who require treatment with uridine diphosphate glucuronosyltransferase (UGT1A1) inhibitors.

• Participants with known homozygous UGT1A1*28 allele if tested during the previous treatment.

• Participants with active infection requiring antibiotics.

• Participants who have not recovered from toxicities or adverse events (AE) related to prior therapy to Grade <= 1 with the following exceptions.

  • Participants with platinum related hypomagnesemia (on replacement) are eligible.
  • Participants with auto-immune thyroid dysfunction on stable replacement therapy are eligible.
  • Participants with any grade alopecia or grade 1 or 2 neuropathy are eligible.

• Participants with a history of gastrointestinal (GI) perforation or hemorrhage (> 30mL bleeding/episode) fistula or hemoptysis within 3 months prior to initiation of study therapy, intra-abdominal abscess in the 6 months prior to entry, history of ascites or pleural effusion requiring paracentesis or thoracentesis in the 4 weeks prior to initiation of study therapy or history of bowel obstruction within 3 months prior to initiation of study therapy.

• Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during SG treatment or within 5 months after the final dose of SG. Note: Seasonal flu vaccines that do not contain a live virus and locally authorized/approved Coronavirus disease 2019 (COVID-19) vaccines are permitted

• Participants with severe uncontrolled intercurrent illness that would limit compliance with study requirements, evaluated by history, physical exam, and chemistry panel.

This study will comply with the National Institutes of Health (NIH) Data Management and Sharing (DMS) Policy, which applies to all new and ongoing NIH-funded research in the intramural research program (IRP), as of January 25, 2023, that is associated with an investigator-initiated intramural research program (ZIA), with a clinical protocol that undergoes scientific review and/or will involve genomic data sharing.

This study will comply with the National Institutes of Health (NIH) Data Management and Sharing (DMS) Policy. Genomic data are available once genomic data are uploaded per protocol Genomic Data Sharing (GDS) plan for as long as database is active.

Data from this study may be requested by contacting the principal investigator (PI). Genomic data are made available via the database of Genotypes and Phenotypes (dbGaP) through requests to the data custodians.